Table 3 Univariate analyses of the effect of variables on overall survival (OS) and disease-free survival (DFS)
OS | DFS | |||
|---|---|---|---|---|
Variable | No. (% survival) | P-value | % DFS | P-value |
Age (years) | 0.36 | 0.22 | ||
<50 | 103 (88) | 73 | ||
>50 | 23 (83) | 55 | ||
Menopausal status | 0.52 | 0.004 | ||
Premenopausal | 100 (88) | |||
Postmenopausal | 26 (85) | |||
Clinical primary tumour (baseline) | 0.01 | 0.14 | ||
T2 | 15 (93) | 80 | ||
T3 | 64 (94) | 80 | ||
T4 | 47 (77) | 57 | ||
Clinical nodal status (baseline) | 0.01 | 0.02 | ||
N0 | 40 (90) | 78 | ||
N1 | 65 (92) | 72 | ||
N2+N3 | 21 (67) | 57 | ||
Clinical stage (baseline) | 0.023 | 0.41 | ||
II | 42 (92) | 79 | ||
IIIA | 35 (94) | 80 | ||
IIIB | 49 (78) | 59 | ||
Tumour grade (known in 110 patients) | 0.43 | 0.20 | ||
G1+G2 | 59 (88) | 73 | ||
G3 | 51 (82) | 63 | ||
Oestrogen receptor | 0.35 | 0.84 | ||
Positive | 53 (87) | 64 | ||
Negative | 43 (93) | 81 | ||
Unknown | 30 (80) | 70 | ||
Progesterone receptor | 0.53 | 0.07 | ||
Positive | 47 (89) | 74 | ||
Negative | 49 (90) | 69 | ||
Unknown | 30 (80) | 70 | ||
Diagnosis to primary chemotherapy (days) | 0.57 | 0.04 | ||
<21 | 94 (86) | 76 | ||
>21 | 32 (90) | 59 | ||
Clinical primary tumour (postneoadjuvant chemotherapy) | 0.004 | 0.64 | ||
T0 | 37 (84) | 70 | ||
T1 | 25 (100) | 80 | ||
T2 | 40 (93) | 77 | ||
T3+T4 | 24 (71) | 54 | ||
Clinical nodal status (postadjuvant chemotherapy) | 0.28 | 0.41 | ||
N0 | 97 (89) | 72 | ||
N1+N2 | 29 (83) | 69 | ||
Clinical response | 0..72 | |||
cCR | 35 (89) | 77 | ||
<cCR | 91 (87) | 69 | ||
Tumour pathologic response (123 patients) | 0.026 | 0.0002 | ||
T0 | 29 (97) | 93 | ||
T1 | 40 (93) | 80 | ||
T2 | 43 (84) | 56 | ||
T3 | 11 (73) | 55 | ||
Primary tumour pathologic response (123 patients) | 0.09 | 0.002 | ||
pCR | 29 (97) | 93 | ||
<pCR | 94 (86) | 66 | ||
Pathological nodal status (122 patients) | 0.08 | 0.0001 | ||
Negative | 42 (95) | 93 | ||
Positive | 80 (86) | 62 | ||
Pathological nodal status (122 patients) | 0.047 | <0.0001 | ||
Negative | 42 (95) | 93 | ||
1–3 positive nodes | 37 (92) | 73 | ||
4–9 positive nodes | 27 (85) | 59 | ||
More than 9 positive nodes | 16 (75) | 44 | ||
Pathologic stage (postneoadjuvant chemotherapy) | 0.017 | 0.0006 | ||
T0N0 | 20 (95) | 95 | ||
I | 13 (100) | 100 | ||
II (A+B) | 81 (86) | 64 | ||
III (A+B) | 12 (67) | 50 | ||
Adjuvant radiotherapy | 0.029 | 0.01 | ||
Yes | 120 (88) | 73 | ||
None | 6 (67) | 33 | ||
Adjuvant tamoxifen (receptor-positive patients only, 57) | 0.46 | 0.51 | ||
Yes (46 patients) | 42 (91) | 70 | ||
No (11 patients) | 9 (82) | 63 |
